zurück | Praevention | |
Allgemeines | ||
Screening |
Stuhltest | Endoskopie |
ASS |
ASS Einnahme vermindert das Risiko von colorektalen Malignomen (1-6). | |
ASS Einnahme verlängert die Überlebenszeit nach Colonkarzinom bei PIK3CA - Mutation, aber nicht bei PIK3CA - Wildtyp(7). | ||
Quellen |
1.) Sandler RS, et al.: A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348(2003):883-90 2.) Burn J, et al.: Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378(2011):2081-7 3.) Algra AM, Rothwell PM: Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13(2012):518-27 4.) Din FV, et al.: Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 59(2010):1670-9 5.) Dubé C, et al.: The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146(2007):365-75 6.) Flossmann E, Rothwell PM.: Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369(2007):1603-13 7.) Liao X, et al.: Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival. N Engl J Med 367(2012):1596-606 |
|